Speciality: Rheumatology
Description:
A warm welcome to all the medical professionals in this interesting session of ACR updates 2021.
In this webinar, an elaborative discussion is done ACR 2021 updates. The viewers are going to get extensive knowledge from the ACR paper and posters. The primary subject of discussion in this webinar is immunological responses in rheumatic diseases. TNF alpha inhibitors and JAK inhibitors are the primary focus of discussion.
The speakers Dr. Vineeta Shobha, Dr Sumit Agarwal and Dr Vishnu Sharma have immense knowledge and experience in the field of rheumatology. In this webinar they have discussed how the TNF alpha inhibitors and JAK inhibitors play a key role in altering immune responses in rheumatological diseases.
TNF alpha inhibitor and JAK inhibitor drugs help in controlling inflammation in different conditions such as rheumatoid arthritis (RA), psoriatic arthritis, juvenile idiopathic arthritis, inflammatory bowel disease (Crohn's and ulcerative colitis), ankylosing spondylitis, and psoriasis.
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
See More Webinars @ Hidoc Webinars
1.
Beyond What Is Visible in Myelofibrosis?
2.
FDA approves rivanetin as the first-line treatment for lung cancer.
3.
In high-risk muscle invasive urothelial cancer, adjuvant pembrolizumab improves disease-free survival.
4.
New First-Line Option for Advanced ALK-Positive Lung Cancer
5.
Certain surgical gestures during prostate removal linked to better sexual function recovery
1.
Tremelimumab: A Potential Breakthrough in Cancer Treatment
2.
The Technological Revolution in Precision Oncology and Tumor Microenvironment Therapy
3.
Artificial Intelligence for Early Cancer Detection Leveraging Multi-Omics: A Comprehensive Review
4.
Harnessing Snake Venom in Hematology: From Toxins to Life-Saving Therapeutics
5.
Unlocking the Potential of SCD: A Comprehensive Guide to Diagnosis and Treatment
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VII
2.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Conclusion
3.
Updates on Standard V/S High Risk Myeloma Treatment
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
5.
Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part I
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation